# Infigratinib in Recurrent High-Grade Glioma Patients

> **NCT04424966** · EARLY_PHASE1 · TERMINATED · sponsor: **Nader Sanai** · enrollment: 7 (actual)

## Conditions studied

- Glioma
- Glioblastoma
- GBM

## Interventions

- **DRUG:** Infigratinib

## Key facts

- **NCT ID:** NCT04424966
- **Lead sponsor:** Nader Sanai
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-07-21
- **Primary completion:** 2023-01-31
- **Final completion:** 2024-02-19
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Study drug no longer available.
- **Last updated:** 2025-10-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04424966

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04424966, "Infigratinib in Recurrent High-Grade Glioma Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04424966. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*